RP-HPLC-UV Method for Simultaneous Estimation of Ceftriaxone

4217 words (17 pages) Essay

9th Oct 2017 Health Reference this

Disclaimer: This work has been submitted by a university student. This is not an example of the work produced by our Essay Writing Service. You can view samples of our professional work here.

Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of UKEssays.com.

A Validated RP-HPLC-UV method for Simultaneous estimation of Ceftriaxone and Sulbactum in Rat Plasma

ABSTRACT:

A reverse phase-liquid chromatographic method with UV detection is developed for simultaneous estimation of ceftriaxone sodium and sulbactam sodium in rat plasma. Drugs were extracted from blank plasma by simple protein precipitation technique. Chromatographic separation of these two drugs was done on Phenomenex C18 column (250mm X 4.6mm, i.d, 5μm) by using mobile phase consisting of 10mM potassium dihydrogen orthophosphate buffer (pH- 5) and acetonitrile (90:10 % v/v). The developed RP-HPLC method had the acceptable symmetrical peaks good resolution and drugs were eluted with good retention time. The developed bio-analytical method was Linear, precise, and accurate with the concentration range of 20-150 μg mL-1 for ceftriaxone and 10-75 μg mL-1 for sulbactam. From the developed method we can moniter ceftriaxone and sulbactam sodium concentrations in rat plasma.

Keywords: Ceftriaxone sodium, Sulbactam sodium, Liquid chromatography, Rat plasma

  1. INTRODUCTION

Ceftriaxone[1] (CFX) is a third generation cephalosporin. Chemically it is (6R,7R)-7-{2-(2-amino-4-thiazolyl)-(Z)-2- [methoxyiminuteo-acetamido]-3{[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3-yl)thio]methyl}-8-oxo-5-thia-l-azobicyclo [4,2,0] oct-2-ene-2-carboxylic acid. Sulbactam (SBM) chemically (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0] heptane -2-carboxylic acid 4,4-dioxide is used as a beta-lactamase inhibitor. Structural formulae of CFX and SBM are given in Fig.1. These drugs are frequently associated in pharmaceutical formulations against meningitis, typhoid, gonorrhoea and urinary tract infections [2].

Sulbactomax is a commercially available pharmaceutical product containing SBM and CFX. The product is available as a dry powder for injection. The product is supplied in different strengths (250 mg+125 mg, 500mg+250 mg, 1gm+0.5gm, 2gm+1gm) of CFX and SBM respectively.

Fig.1.Chemical structure of CFX and SBM

Sulbactomax is a synergistic antimicrobial mixture with clear in vitro antibacterial activity against a wide spectrum of organisms. SBM not only increases the antibacterial activity of CFX but also shows a moderate antibacterial activity by forming a protein complex with beta-lactamas by irreversibly blockin their destructive hydrolytic activity.

Get Help With Your Essay

If you need assistance with writing your essay, our professional essay writing service is here to help!

Find out more

Thus, SBM increases the spectrum of activity of CFX. This SBM also binds with some penicillin binding proteins, sensitive strains are often considered more susceptible to the Sulbactomax than CFX alone. In bacterial strains that produce either low amounts of beta– lactamase, or none at all, a synergistic effect is witnessed when SBM is associated with CFX that has a complementary affinity for the target sites.

Sulbactomax has good active against all the microorganisms which are sensitive/resistant to CFX. Further, it also demonstrates synergistic activity (decrease in minimum inhibitory concentrations for the combination versus those of each component) in a variety of organisms. So it has improved efficacy as compared to CFX alone, lesser side effects, wider spectrum coverage and better results of bacterial MIC (minimum inhibitory concentration) makes this product unique in the world.

A literature survey revealed a spectrophotometric [3], spectrofluorimetric in human plasma [4], HPLC for the estimation of marketed formulations [5,6], in human plasma [7] and for the determination of pharmacokinetics in dogs [8], capillary electrophoresis [9] and GC-MS [10] methods for the estimation of CFX and SBM individually and in combined forms.

However, from the literature survey there was no method development reported for the simultaneous estimation of CFX and SBM by HPLC in rat plasma. The present communication describes an isocratic liquid chromatography (LC) method for simultaneous determination of CFX sodium and SBM, which can be used for the quality control of the formulation developed and other biological applications.

  1. Experimental
    1. Chemicals and Reagents

All chemicals and reagents used were of analytical grade only. Milli-Q-water was used throughout the process and acetonitrile of HPLC grade were procured from Merck Chemical Laboratories, Bangalore, India. Commercial formulation, CetriaxS injection containing ceftriaxone sodium 1gm and sulbactam sodium 0.5 gm were obtained from the local market. Blank rat plasma was obtained from JSS Medical College and Hospital, Mysore, India.

  1. Instrumentation and Analytical Conditions

A HPLC with the UV detector was used for this research work. Here the separation was done using Phenomenex C-18 column. The mobile phase was a mixture of phosphate Buffer (pH adjusted to 5 with potassium hydroxide) and acetonitrile (90:10) v/v. The mobile phase was filtered through 0.45 μ membrane filter before its use, degassed with a helium sparge for 15min at flow rate of 1.0 mL min-1. The column was maintained at room temperature 20±100C. The injection volume of samples was 10 μL. The analyte was monitored at wavelength of 230 nm and optimized chromatographic conditions are shown in Table-1.

2.3.Preparation of mobile phase:

Phosphate buffer of pH 5 was prepared by dissolving 1.36 gm ofPotassiumdihydrogenorthophosphate in 1000 mL of water and it was sonicated for 5 minutes, then the pH was adjusted using potassium hydroxide solution. It was than filtered by vaccum filteration. Finally the mobile phase was prepared by mixing phosphate buffer and acetonitrile in the ratio 90:10v/v.

2.4.Preparation of standard and sample solution

SeparatelyweighedquantityofCFXsodium(10mg)andSBMsodium (10mg)was transferred into a 100mL volumetricflaskandmadeupto100mLwithwatertoget100 µg mL-1 ofCFXsodiumand100 µg mL-1 ofSBM. From this, different solutions containing the mixture of CFXsodium(20-150 µg mL-1) and SBMsodium(10-75 µg mL-1) were prepared.

For the preparation of sample solution, Cetriax-Spowder for injection(containing1gmof CFXand0.5gmof SBM)was transferred to a 100 mL volumetric flask. Distilled water was added, and then swirled to dissolve it, diluted to 100 mL with the same solvent.

2.5.Preparation of calibration curve:

Five different concentrated solutions containing mixture of CFX (20-150 µg mL-1) and SBM (10-75 µg mL-1) were injected onto HPLC. A calibration curve was prepared taking concentrations on X-axis and Peak Area on Y-Axis.

2.6.Preparation of plasma samples:

Plasma samples of CFX and SBM was prepared by the protein precipitation method. A blank was prepared by taking 0.1mL of rat plasma and to this 1.9 mL of acetonitrile was added and sample was prepared by taking 0.1 mL of combination of CFX and SBM (which were mixed in equal volumes) and 0.1 mL of rat plasma was added to the 2 mL Eppendorf tubes containing 1.8 mL of acetonitrile. These samples were centrifuged for 10 min at 10,000 rpm. The supernatant solution filtered through 0.45µ syringe filter and transferred to HPLC vials.

  1. RESULTS AND DISCUSSION

3.1 Method Development

Taking into consideration, the instability of CFX and SBM in strong alkaline and strong acidic condition, the pH value of the mobile phase should be limited within the range of 3‐7, since mild acidic pH favours the retention and separation of two drugs on C‐18 column.

After few trials, phosphate buffer with pH 5 was finalized. The method development started with the methanol and phosphate buffer as drugs did not elute in this mobile phase, so the organic phase was altered from methanol to acetonitrile. Both CFX and SBM in the mobile phase have no significant UV maximum, the wavelength of 230 nm was employed for the detection. After few trails Phenomenex C-18 column and binary mixture of phosphate buffer (pH 5) and acetonitrile (90:10 % v/v) was optimized as mobile phase which produced symmetric peak shape, good resolution and reasonable retention time for both the drugs (Table 1). The retention times of CFX and SBM for six repetitions were found to be 7.8 ± 0.02 min and 4.7 ± 0.006 respectively (Fig.2).

(a)

(b)

Fig.2. LC chromatogram of rat blank plasma (a) plasma spiked with standard CFX and SBM(b)

Table 1. Optimized chromatographic conditions

Parameter

Optimized condition

Chromatograph

HPLC with UV- detector

Column

C18 Column

Mobile Phase

Acetonitrile and pH-5 buffer in the ratio of 10:90(v/v)

Flow rate

1.00 mL min-1

Detection

230nm

Injection volume

10 μL

Temperature column

Room temperature

3.2.Method validation

Validation is a process of establishing documented evidence, which offers a high degree of assurance that a specific activity will steadily yield anticipated result or product meeting its predetermined specifications and quality features [11]. The method was validated for different parameters like linearity, precision, recovery, accuracy, selectivity and sensitivity [12].

3.2.1Selectivity

Selectivity is defined as, “the capability of an analytical method to distinguish and measure the analyte in the presence of other components in the sample [12]”. Selectivity is calculated by injecting extracted blank plasma and relating with the response of extracted LLOQ samples. Both the peaks of Ceftriaxone and Sulbactum did not interfere with any endogenous components.

3.2.2Sensitivity

Sensitivity is measured using Lower Limit of Quantification (LLOQ). LLOQ is the lowest concentration of the standard curve that can be measured with acceptable accuracy and precision [12]”. The LLOQ was established using five samples independent of standards and determined the co-efficient of variation and appropriate confidence interval.

3.2.3.Linearity of Response

To demonstrate the linearity of response, series of solutions ranging from (20-150 µg mL-1) of CFX and SBM of (10-75 µg mL-1) were prepared and injected onto the HPLC system following the described conditions. The graph was constructed between concentration vs. peak area and it was found that correlation co-efficient and regression analysis were within the limits and the results are summarized in the Table 2, and the calibration graphs are shown in Fig. 3 and Fig. 4 for CFX and SBM respectively.

Fig.3. Calibration graph of CFX

Fig.4. Calibration graph of SBM

Table 2. Linearity of CFX and SBM

Parameters

CFX

SBM

Retention time (min)

7.3

4.6

Linear range (ppm) [n=6]

(µg mL-1)

20-150

10-75

Correlation coefficient (r2)

0.996

0.997

Slope

1513.1

155.58

Intercept

272333

61596

Lowest limit of quatification LLOQ (µg mL-1)

0.87

0.96

3.2.4.Recovery

“The recovery of an analyte is the detector response achieved from an quantity of the analyte added to and extracted from the biological matrix, correlated to the detector response found for the true concentration of the pure authentic standard”[12]. “Recovery of the analyte is not necessary be 100%” [12]. This experiments were performed by comparing the analytical results for extracted samples at three different concentrations (low, medium, and high) with unextracted standards that represent 100% recovery. Results are summarised in Table 3.

Table 3. Recovery studies of CFX sodium and SBM

Concentration of CFX and sulbactam

Amount recovered% for CFX

Amount recovered% for SBM

Low

98.7%

99.9%

Medium

96.8%

98.9%

High

99.3%

98.6%

3.2.5.Accuracy and Precision

For validation of this bioanalytical method, precision and accuracy should be determined using minimum of five determinations per concentration level (excluding blank samples). The mean value should be within ± 15% of the theoretical value, except at LLOQ, where it must not differ by more than ± 20%. The accuracy and precision around the mean value should not be beyond 15% of the CV except for LLOQ, where it should not exceed by 20% of the CV.

The accuracy of the analytical method defines the closeness of agreement between the test value and the reference value. The precision of the analytical method describes the closeness of frequent individual measures of analyte. Accuracy is expressed in terms of % obtained. Precision is expressed in terms of coefficient of variation (CV). The statistical method for determination of the accuracy and precision should be predefined and calculated according standard practise. Accuracy and Precision should be demonstrated for the low, medium, high and LLOQ QC samples, within a single run and between different runs results are summarised in Table 4 & 5.

% CV (precision) =100 x Standard deviation/Mean

Table 4. Accuracy and Precision of CFX

Theoretical concentration

(µg/mL)

Measured concentration (µg/mL)

Intra-day

Inter-day

%CV

Accuracy (%)

%CV

Accuracy (%)

20

0.98

98.4

1.42

96.1

100

0.76

103.7

1.32

102.3

150

1.34

99.5

1.7

98.7

Table 5. Accuracy and Precision of SLB

Theoretical concentration

µg mL-1

Measured concentration (µg mL-1)

Intra-day

Inter-day

%CV

Accuracy (%)

%CV

Accuracy (%)

10

0.96

101.7

0.76

95.6

50

1.00

99.8

1.2

103.4

75

1.02

97.3

1.04

97.4

3.2.6.Stability studies

Freeze and Thaw Stability

Stability of analyte was determined with three freeze and thaw cycles. All the three aliquots at low, medium and high concentrations were stored at the proposed storage temperature for 24 hours and defrosted unassisted at room temperature. When completely thawed, the samples were again frozen for 12 to 24 hours under the same conditions. The same cycle was repeated two more times, and then analyzed after the third cycle.

Short-Term Temperature Stability

Three aliquots of low, medium and high concentrations were thawed at room temperature and at this temperature sample was kept from 4 to 24 hours and analyzed.

Long-Term Stability

The storage time in a long-term stability assessment should surpass the time between the date of first sample collection and the date of last sample analysis. Long-term stability was determined by storing three aliquots of the low, medium and high concentrations under the same conditions as that of the study samples. The concentrations of all the stability samples were related to the mean of back-calculated values for the standards at the suitable concentrations from the first day of long-term stability testing.

Stock Solution Stability

The stability of stock solutions of drug was estimated at room temperature for 6 hours. After the desired storage time, the stability was confirmed by comparing the instrument response with that of newly prepared solutions Results are summarised in Table 6.

Table 6. Stability studies of CFX and SBM

Stability

µg mL-1 (error %)

CFX

µg mL-1 (error %)

SBM

20

100

150

10

50

75

Freeze-thaw

84.5

93.3

94.9

88.5

96.3

97.9

Long term

100.5

100.6

100.8

100.5

101.6

100.8

Short term

93.9

97.6

101.4

93.9

93.6

103.4

Stock Solution

95.6

97.6

93.2

95.3

96.8

98.5

  1. SUMMARY

In this work, a simple, stability indicating, accurate and validated stability indicating HPLC method for the simultaneous determination of ceftriaxone and sulbactam in their pharmaceutical formulation was developed. The method was validated according to FDA guidelines. CFX and SBM were eluted at 7.3 min and 4.6 min respectively. The correlation coefficient (r2) for CFX and SBM were found to be 0.996 and 0.9976 respectively. Lower Limit of quantification (LLOQ) was found to be 0.87 µg mL-1 for ceftriaxone and 0.96 µg mL-1 for sulbactam. The %CV for the intraday and interday precision were found to be <2.

  1. CONCLUSION

The method includes simple and precise method for simultaneous determination of CFX sodium and SBM. It produces symmetrical peak shape, good resolution and reasonable retention time for both drugs. So this method can be appropriate for the  simultaneous estimation of CFX sodium and SBM in quality control studies for routine analysis.

  1. AKNOWLEDGMENT

The authors are thankful to The Principal, JSS College of Pharmacy, JSS University, Mysore for providing all necessary facilities to carry out the research. The authors are also thankful to Strides Arco labs, Bangalore for providing the pure salbactum sodium and ceftriaxone sodium as gift samples.

References

A Validated RP-HPLC-UV method for Simultaneous estimation of Ceftriaxone and Sulbactum in Rat Plasma

ABSTRACT:

A reverse phase-liquid chromatographic method with UV detection is developed for simultaneous estimation of ceftriaxone sodium and sulbactam sodium in rat plasma. Drugs were extracted from blank plasma by simple protein precipitation technique. Chromatographic separation of these two drugs was done on Phenomenex C18 column (250mm X 4.6mm, i.d, 5μm) by using mobile phase consisting of 10mM potassium dihydrogen orthophosphate buffer (pH- 5) and acetonitrile (90:10 % v/v). The developed RP-HPLC method had the acceptable symmetrical peaks good resolution and drugs were eluted with good retention time. The developed bio-analytical method was Linear, precise, and accurate with the concentration range of 20-150 μg mL-1 for ceftriaxone and 10-75 μg mL-1 for sulbactam. From the developed method we can moniter ceftriaxone and sulbactam sodium concentrations in rat plasma.

Keywords: Ceftriaxone sodium, Sulbactam sodium, Liquid chromatography, Rat plasma

  1. INTRODUCTION

Ceftriaxone[1] (CFX) is a third generation cephalosporin. Chemically it is (6R,7R)-7-{2-(2-amino-4-thiazolyl)-(Z)-2- [methoxyiminuteo-acetamido]-3{[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3-yl)thio]methyl}-8-oxo-5-thia-l-azobicyclo [4,2,0] oct-2-ene-2-carboxylic acid. Sulbactam (SBM) chemically (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0] heptane -2-carboxylic acid 4,4-dioxide is used as a beta-lactamase inhibitor. Structural formulae of CFX and SBM are given in Fig.1. These drugs are frequently associated in pharmaceutical formulations against meningitis, typhoid, gonorrhoea and urinary tract infections [2].

Sulbactomax is a commercially available pharmaceutical product containing SBM and CFX. The product is available as a dry powder for injection. The product is supplied in different strengths (250 mg+125 mg, 500mg+250 mg, 1gm+0.5gm, 2gm+1gm) of CFX and SBM respectively.

Fig.1.Chemical structure of CFX and SBM

Sulbactomax is a synergistic antimicrobial mixture with clear in vitro antibacterial activity against a wide spectrum of organisms. SBM not only increases the antibacterial activity of CFX but also shows a moderate antibacterial activity by forming a protein complex with beta-lactamas by irreversibly blockin their destructive hydrolytic activity.

Thus, SBM increases the spectrum of activity of CFX. This SBM also binds with some penicillin binding proteins, sensitive strains are often considered more susceptible to the Sulbactomax than CFX alone. In bacterial strains that produce either low amounts of beta– lactamase, or none at all, a synergistic effect is witnessed when SBM is associated with CFX that has a complementary affinity for the target sites.

Sulbactomax has good active against all the microorganisms which are sensitive/resistant to CFX. Further, it also demonstrates synergistic activity (decrease in minimum inhibitory concentrations for the combination versus those of each component) in a variety of organisms. So it has improved efficacy as compared to CFX alone, lesser side effects, wider spectrum coverage and better results of bacterial MIC (minimum inhibitory concentration) makes this product unique in the world.

A literature survey revealed a spectrophotometric [3], spectrofluorimetric in human plasma [4], HPLC for the estimation of marketed formulations [5,6], in human plasma [7] and for the determination of pharmacokinetics in dogs [8], capillary electrophoresis [9] and GC-MS [10] methods for the estimation of CFX and SBM individually and in combined forms.

However, from the literature survey there was no method development reported for the simultaneous estimation of CFX and SBM by HPLC in rat plasma. The present communication describes an isocratic liquid chromatography (LC) method for simultaneous determination of CFX sodium and SBM, which can be used for the quality control of the formulation developed and other biological applications.

  1. Experimental
    1. Chemicals and Reagents

All chemicals and reagents used were of analytical grade only. Milli-Q-water was used throughout the process and acetonitrile of HPLC grade were procured from Merck Chemical Laboratories, Bangalore, India. Commercial formulation, CetriaxS injection containing ceftriaxone sodium 1gm and sulbactam sodium 0.5 gm were obtained from the local market. Blank rat plasma was obtained from JSS Medical College and Hospital, Mysore, India.

  1. Instrumentation and Analytical Conditions

A HPLC with the UV detector was used for this research work. Here the separation was done using Phenomenex C-18 column. The mobile phase was a mixture of phosphate Buffer (pH adjusted to 5 with potassium hydroxide) and acetonitrile (90:10) v/v. The mobile phase was filtered through 0.45 μ membrane filter before its use, degassed with a helium sparge for 15min at flow rate of 1.0 mL min-1. The column was maintained at room temperature 20±100C. The injection volume of samples was 10 μL. The analyte was monitored at wavelength of 230 nm and optimized chromatographic conditions are shown in Table-1.

2.3.Preparation of mobile phase:

Phosphate buffer of pH 5 was prepared by dissolving 1.36 gm ofPotassiumdihydrogenorthophosphate in 1000 mL of water and it was sonicated for 5 minutes, then the pH was adjusted using potassium hydroxide solution. It was than filtered by vaccum filteration. Finally the mobile phase was prepared by mixing phosphate buffer and acetonitrile in the ratio 90:10v/v.

2.4.Preparation of standard and sample solution

SeparatelyweighedquantityofCFXsodium(10mg)andSBMsodium (10mg)was transferred into a 100mL volumetricflaskandmadeupto100mLwithwatertoget100 µg mL-1 ofCFXsodiumand100 µg mL-1 ofSBM. From this, different solutions containing the mixture of CFXsodium(20-150 µg mL-1) and SBMsodium(10-75 µg mL-1) were prepared.

For the preparation of sample solution, Cetriax-Spowder for injection(containing1gmof CFXand0.5gmof SBM)was transferred to a 100 mL volumetric flask. Distilled water was added, and then swirled to dissolve it, diluted to 100 mL with the same solvent.

2.5.Preparation of calibration curve:

Five different concentrated solutions containing mixture of CFX (20-150 µg mL-1) and SBM (10-75 µg mL-1) were injected onto HPLC. A calibration curve was prepared taking concentrations on X-axis and Peak Area on Y-Axis.

2.6.Preparation of plasma samples:

Plasma samples of CFX and SBM was prepared by the protein precipitation method. A blank was prepared by taking 0.1mL of rat plasma and to this 1.9 mL of acetonitrile was added and sample was prepared by taking 0.1 mL of combination of CFX and SBM (which were mixed in equal volumes) and 0.1 mL of rat plasma was added to the 2 mL Eppendorf tubes containing 1.8 mL of acetonitrile. These samples were centrifuged for 10 min at 10,000 rpm. The supernatant solution filtered through 0.45µ syringe filter and transferred to HPLC vials.

  1. RESULTS AND DISCUSSION

3.1 Method Development

Taking into consideration, the instability of CFX and SBM in strong alkaline and strong acidic condition, the pH value of the mobile phase should be limited within the range of 3‐7, since mild acidic pH favours the retention and separation of two drugs on C‐18 column.

After few trials, phosphate buffer with pH 5 was finalized. The method development started with the methanol and phosphate buffer as drugs did not elute in this mobile phase, so the organic phase was altered from methanol to acetonitrile. Both CFX and SBM in the mobile phase have no significant UV maximum, the wavelength of 230 nm was employed for the detection. After few trails Phenomenex C-18 column and binary mixture of phosphate buffer (pH 5) and acetonitrile (90:10 % v/v) was optimized as mobile phase which produced symmetric peak shape, good resolution and reasonable retention time for both the drugs (Table 1). The retention times of CFX and SBM for six repetitions were found to be 7.8 ± 0.02 min and 4.7 ± 0.006 respectively (Fig.2).

(a)

(b)

Fig.2. LC chromatogram of rat blank plasma (a) plasma spiked with standard CFX and SBM(b)

Table 1. Optimized chromatographic conditions

Parameter

Optimized condition

Chromatograph

HPLC with UV- detector

Column

C18 Column

Mobile Phase

Acetonitrile and pH-5 buffer in the ratio of 10:90(v/v)

Flow rate

1.00 mL min-1

Detection

230nm

Injection volume

10 μL

Temperature column

Room temperature

3.2.Method validation

Validation is a process of establishing documented evidence, which offers a high degree of assurance that a specific activity will steadily yield anticipated result or product meeting its predetermined specifications and quality features [11]. The method was validated for different parameters like linearity, precision, recovery, accuracy, selectivity and sensitivity [12].

3.2.1Selectivity

Selectivity is defined as, “the capability of an analytical method to distinguish and measure the analyte in the presence of other components in the sample [12]”. Selectivity is calculated by injecting extracted blank plasma and relating with the response of extracted LLOQ samples. Both the peaks of Ceftriaxone and Sulbactum did not interfere with any endogenous components.

3.2.2Sensitivity

Sensitivity is measured using Lower Limit of Quantification (LLOQ). LLOQ is the lowest concentration of the standard curve that can be measured with acceptable accuracy and precision [12]”. The LLOQ was established using five samples independent of standards and determined the co-efficient of variation and appropriate confidence interval.

3.2.3.Linearity of Response

To demonstrate the linearity of response, series of solutions ranging from (20-150 µg mL-1) of CFX and SBM of (10-75 µg mL-1) were prepared and injected onto the HPLC system following the described conditions. The graph was constructed between concentration vs. peak area and it was found that correlation co-efficient and regression analysis were within the limits and the results are summarized in the Table 2, and the calibration graphs are shown in Fig. 3 and Fig. 4 for CFX and SBM respectively.

Fig.3. Calibration graph of CFX

Fig.4. Calibration graph of SBM

Table 2. Linearity of CFX and SBM

Parameters

CFX

SBM

Retention time (min)

7.3

4.6

Linear range (ppm) [n=6]

(µg mL-1)

20-150

10-75

Correlation coefficient (r2)

0.996

0.997

Slope

1513.1

155.58

Intercept

272333

61596

Lowest limit of quatification LLOQ (µg mL-1)

0.87

0.96

3.2.4.Recovery

“The recovery of an analyte is the detector response achieved from an quantity of the analyte added to and extracted from the biological matrix, correlated to the detector response found for the true concentration of the pure authentic standard”[12]. “Recovery of the analyte is not necessary be 100%” [12]. This experiments were performed by comparing the analytical results for extracted samples at three different concentrations (low, medium, and high) with unextracted standards that represent 100% recovery. Results are summarised in Table 3.

Table 3. Recovery studies of CFX sodium and SBM

Concentration of CFX and sulbactam

Amount recovered% for CFX

Amount recovered% for SBM

Low

98.7%

99.9%

Medium

96.8%

98.9%

High

99.3%

98.6%

3.2.5.Accuracy and Precision

For validation of this bioanalytical method, precision and accuracy should be determined using minimum of five determinations per concentration level (excluding blank samples). The mean value should be within ± 15% of the theoretical value, except at LLOQ, where it must not differ by more than ± 20%. The accuracy and precision around the mean value should not be beyond 15% of the CV except for LLOQ, where it should not exceed by 20% of the CV.

The accuracy of the analytical method defines the closeness of agreement between the test value and the reference value. The precision of the analytical method describes the closeness of frequent individual measures of analyte. Accuracy is expressed in terms of % obtained. Precision is expressed in terms of coefficient of variation (CV). The statistical method for determination of the accuracy and precision should be predefined and calculated according standard practise. Accuracy and Precision should be demonstrated for the low, medium, high and LLOQ QC samples, within a single run and between different runs results are summarised in Table 4 & 5.

% CV (precision) =100 x Standard deviation/Mean

Table 4. Accuracy and Precision of CFX

Theoretical concentration

(µg/mL)

Measured concentration (µg/mL)

Intra-day

Inter-day

%CV

Accuracy (%)

%CV

Accuracy (%)

20

0.98

98.4

1.42

96.1

100

0.76

103.7

1.32

102.3

150

1.34

99.5

1.7

98.7

Table 5. Accuracy and Precision of SLB

Theoretical concentration

µg mL-1

Measured concentration (µg mL-1)

Intra-day

Inter-day

%CV

Accuracy (%)

%CV

Accuracy (%)

10

0.96

101.7

0.76

95.6

50

1.00

99.8

1.2

103.4

75

1.02

97.3

1.04

97.4

3.2.6.Stability studies

Freeze and Thaw Stability

Stability of analyte was determined with three freeze and thaw cycles. All the three aliquots at low, medium and high concentrations were stored at the proposed storage temperature for 24 hours and defrosted unassisted at room temperature. When completely thawed, the samples were again frozen for 12 to 24 hours under the same conditions. The same cycle was repeated two more times, and then analyzed after the third cycle.

Short-Term Temperature Stability

Three aliquots of low, medium and high concentrations were thawed at room temperature and at this temperature sample was kept from 4 to 24 hours and analyzed.

Long-Term Stability

The storage time in a long-term stability assessment should surpass the time between the date of first sample collection and the date of last sample analysis. Long-term stability was determined by storing three aliquots of the low, medium and high concentrations under the same conditions as that of the study samples. The concentrations of all the stability samples were related to the mean of back-calculated values for the standards at the suitable concentrations from the first day of long-term stability testing.

Stock Solution Stability

The stability of stock solutions of drug was estimated at room temperature for 6 hours. After the desired storage time, the stability was confirmed by comparing the instrument response with that of newly prepared solutions Results are summarised in Table 6.

Table 6. Stability studies of CFX and SBM

Stability

µg mL-1 (error %)

CFX

µg mL-1 (error %)

SBM

20

100

150

10

50

75

Freeze-thaw

84.5

93.3

94.9

88.5

96.3

97.9

Long term

100.5

100.6

100.8

100.5

101.6

100.8

Short term

93.9

97.6

101.4

93.9

93.6

103.4

Stock Solution

95.6

97.6

93.2

95.3

96.8

98.5

  1. SUMMARY

In this work, a simple, stability indicating, accurate and validated stability indicating HPLC method for the simultaneous determination of ceftriaxone and sulbactam in their pharmaceutical formulation was developed. The method was validated according to FDA guidelines. CFX and SBM were eluted at 7.3 min and 4.6 min respectively. The correlation coefficient (r2) for CFX and SBM were found to be 0.996 and 0.9976 respectively. Lower Limit of quantification (LLOQ) was found to be 0.87 µg mL-1 for ceftriaxone and 0.96 µg mL-1 for sulbactam. The %CV for the intraday and interday precision were found to be <2.

  1. CONCLUSION

The method includes simple and precise method for simultaneous determination of CFX sodium and SBM. It produces symmetrical peak shape, good resolution and reasonable retention time for both drugs. So this method can be appropriate for the  simultaneous estimation of CFX sodium and SBM in quality control studies for routine analysis.

  1. AKNOWLEDGMENT

The authors are thankful to The Principal, JSS College of Pharmacy, JSS University, Mysore for providing all necessary facilities to carry out the research. The authors are also thankful to Strides Arco labs, Bangalore for providing the pure salbactum sodium and ceftriaxone sodium as gift samples.

References

  1. Rang HP, Dale MM (1993). Pharmacology, (2nd ed.). Churchill Livingstone, ELBS.
  2. Physicians Desk Reference (1997). American Academy of Physician Assistants (51th ed).
  3. Patel FM, Dave JB , Patel CN, spectrophotometric methods for simultaneous estimation of cefuroxime sodium and sulbactam sodium in injecton, International journal of pharmaceutical sciences and research.2012; 3(9), 3513-3517.
  4. Jasmin Shah,Rasul Jan M,Sultan Shah,Naeem M, Spectrofluorimetric Protocol for Ceftriaxone in Commercial Formulation and Human Plasma After Condensation with Formaldehyde and Ethyl Acetoacetate, Journal of Fluorescence.2011; 21(6), 2155-2163.
  5. Shrivastava SM, Singh R, Ariq A, Siddiqui MR, Yadav J, Negi PS, Chaudhary M, A novel high performance liquid chromatographic method for simultaneous determination of ceftriaxone and sulbactam in sulbactomax, Inter Journal of Biomed Sci. 2009; 5(1), 37-43.
  6. Durairaj S, Annadurai T, Palani Kumar B, Arunkumar S, Simultaneous Estimation of Ceftriaxone Sodium and Sulbactam Sodium using Multi-Component Mode of Analysis, Inter Journal of ChemTech Research. 2010; 2(4), 2177-2181.
  7. Huang Ying, Liang Maozhi, Yu Qin, Jiang Lei,Shi Yingkang, Determination of ceftriaxone in human plasma by HPLC, Chinease Journal of Antibiotics.2000; 25,109.
  8. Zhao Xi, Zhang Dan, Chen Hong, Determination of cefotaxime/sulbactam in plasma and pharmacokinetics in dogs by high performance liquid chromatography. Zhongguo Kangshengsu Zazhi. 2004; 29(10): 614-616.
  9. Jelinek I, Krejcirova H, Dohan J, Roubal Z, Determination of sulbactam in human serum using capillary electrophoresis,Cesk Farm.1990; 39,305–307.
  10. Foulds G, Gans DJ, Girard D, Whall TJ, Assays of sulbactam in the presence of ampicillin.Therm Drug Monit.1986;2,223–237.
  11. Lloyd RS, Joseph JK, Joseph LG (1997). Practical HPLC Method Development (2ndedition) New York: Wiley-Blackwell.
  12. FDAUS. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD, USA: US Department of Health and human services, US FDA/Center for Drug Evaluation and Research; 2001.

Cite This Work

To export a reference to this article please select a referencing stye below:

Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.

Related Services

View all

DMCA / Removal Request

If you are the original writer of this essay and no longer wish to have your work published on the UKDiss.com website then please: